NBIX Maintained by Citigroup -- Price Target Raised to $253

gurufocus.com · 2026-09-03

Analyst Rating Update for Neurocrine Biosciences (NBIX)On September 3, 2026, Citigroup maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the

TickrTrends take: Citigroup's raised price target to $253 for NBIX reflects analyst confidence in the company's prospects within the Healthcare sector. Given TickrTrends' current assessment that NBIX is undervalued, this analyst action may support the case for a gap between current market pricing and the firm's estimated fair value. Valuation-focused readers should monitor whether this maintained rating from a major institution influences market perception of NBIX's true worth relative to its fundamentals.

Read the full story at gurufocus.com →